Navneet Arora, MD
Critical Care Medicine · Matthews, NCNPI 1821367228
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,925 of the $22,814 with a category attached, or 69.8%. Dentsply Sirona Inc accounts for 73.4% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $13,058 and has fallen 62.7% since, to $4,877 in 2025. Among critical care medicine clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $495.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dentsply Sirona Inc$17K
- Intuitive Surgical$5K
- Medtronic$168
- GSK$141
- Actelion Pharmaceuticals US, Inc.$128
- AstraZeneca$68
- plus $229 from 10 others
What the payments were for
- Speaking & faculty fees$15,92570%
- Travel & lodging$2,1389%
- Food & beverage$7383%
- Education$4,01318%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dentsply Sirona Inc | 7 | $16,756 |
| Intuitive Surgical | 11 | $5,324 |
| Medtronic | 2 | $168 |
| GSK | 7 | $141 |
| Actelion Pharmaceuticals US, Inc. | 2 | $128 |
| AstraZeneca | 4 | $68 |
| Novartis | 2 | $38 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $36 |
| Insmed, Inc. | 1 | $35 |
| Merck | 2 | $27 |
| Boehringer Ingelheim | 1 | $21 |
| Electromed, Inc. | 1 | $18 |
| Grifols USA, LLC | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Pulmonx Corporation | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,221
- ILLUMISITE$151
How this compares
$22,814 in reported general payments places this provider in the 90th percentile of 190 critical care medicine providers in North Carolina.
See all critical care medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 21 | $271,992 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 235 | $179,924 |
| Breo ElliptaFluticasone/Vilanterol | 146 | $87,978 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 114 | $77,414 |
| Spiriva RespimatTiotropium Bromide | 115 | $67,685 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 91 | $56,096 |
| Incruse ElliptaUmeclidinium Bromide | 104 | $35,887 |
| Arnuity ElliptaFluticasone Furoate | 107 | $33,257 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $30,520 |
| Spiriva HandihalerTiotropium Bromide | 23 | $20,641 |
| EliquisApixaban | 29 | $18,268 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $15,480 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $8,960 |
| Pirfenidone | 11 | $7,594 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $6,761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $141 | $414,461706 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $21 | $379,157186 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $68 | $77,468161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 190 critical care medicine providers in North Carolina.
Other critical care medicine in Matthews
- Souheil Abdel NourMatthews$2K
- Maciej WalczyszynMatthews$2K
- Alexis SmithHuntersville$726K
- Rabih BecharaCharlotte$453K
- Ashish KhannaWinston Salem$364K
- Alan HeffnerCharlotte$326K
- Daniel FeinsteinPinehurst$213K
- Daniel FoxRaleigh$133K
- Hassan YousafWinston Salem$97K
- Neil MacintyreDurham$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.